The mammalian heartbeat is thought to begin just prior to the linear heart tube stage of development. How the initial contractions are established and the downstream consequences of the earliest contractile function on cardiac differentiation and morphogenesis have not been described. Using high-resolution live imaging of mouse embryos, we observed randomly distributed spontaneous asynchronous Ca2+-oscillations (SACOs) in the forming cardiac crescent (stage E7.75) prior to overt beating. Nascent contraction initiated at around E8.0 and was associated with sarcomeric assembly and rapid Ca2+ transients, underpinned by sequential expression of the Na+-Ca2+ exchanger (NCX1) and L-type Ca2+ channel (LTCC). Pharmacological inhibition of NCX1 and LTCC revealed rapid development of Ca2+ handling in the early heart and an essential early role for NCX1 in establishing SACOs through to the initiation of beating. NCX1 blockade impacted on CaMKII signalling to down-regulate cardiac gene expression, leading to impaired differentiation and failed crescent maturation.https://doi.org/10.7554/eLife.17113.001
The heart is the first organ to form and to begin working in an embryo during pregnancy. It must begin pumping early to supply oxygen and nutrients to the developing embryo. Coordinated contractions of specialised muscle cells in the heart, called cardiomyocytes, generate the force needed to pump blood. The flow of calcium ions into and out of the cardiomyocytes triggers these heartbeats. In addition to triggering heart contractions, calcium ions also act as a messenger that drives changes in which genes are active in the cardiomyocytes and how these cells behave.
Scientists commonly think of the first heartbeat as occurring after a tube-like structure forms in the embryo that will eventually develop into the heart. However, it is not yet clear how the first heartbeat starts or how the initial heartbeats affect further heart development.
Tyser, Miranda et al. now show that the first heartbeat actually occurs much earlier in embryonic development than widely appreciated. In the experiments, videos of live mouse embryos showed that prior to the first heartbeat the flow of calcium ions between different cardiomyocytes is not synchronised. However, as the heart grows these calcium flows become coordinated leading to the first heartbeat. The heartbeats also become faster as the heart grows. Using drugs to block the movement of calcium ions, Tyser, Miranda et al. also show that a protein called NCX1 is required to trigger the calcium flows prior to the first heartbeat. Moreover, the experiments revealed that these early heartbeats help drive the growth of cardiomyocytes and shape the developing heart.
Together, the experiments show that the first heartbeats are essential for normal heart development. Future studies are needed to determine what controls the speed of the first heartbeats, and what organises the calcium flows that trigger the first heartbeat. Such studies may help scientists better understand birth defects of the heart, and may suggest strategies to rebuild hearts that have been damaged by a heart attack or other injury.https://doi.org/10.7554/eLife.17113.002
The heart is the first organ to form and function during mammalian embryonic development. In the mouse, mesoderm originating from the primitive streak forms a bilateral pool of progenitor cells that at E7.5 give rise to the cardiac crescent (CC). The CC subsequently expands and migrates to the midline whereupon, between E8.25 and E8.5, the two sides of the CC fuse and form the linear heart tube (LHT) (reviewed in Buckingham et al., 2005). The first cardiac contractions have been described during the transition from CC to LHT. Studies of heart development in model organisms have historically focused on the origin and spatial-temporal allocation of cardiac progenitors and cardiovascular lineage determination (Buckingham et al., 2005; Saga et al., 1996; Cai et al., 2003; Meilhac et al., 2004; Wu et al., 2006; Moretti et al., 2006; Evans et al., 2010; Devine et al., 2014). Whilst insight into the identification and regulation of cardiac cell types is important for improved understanding of congenital heart disease (Bruneau, 2008), an anatomical and cellular bias has overlooked a role for the onset of cardiac function. Early descriptions of initial cardiac contractions (Navaratnam et al., 1986), including suggested pacemaker activity on either side of the embryonic midline (Goss, 1952), as well as optical mapping of spontaneous action potentials performed in both chicken (7 somite stage) and rat (3-somite stage) (Fujii et al., 1981; Hirota et al., 1985), have been informative, but lack resolution. Subsequent studies in mouse (3-somite stage) could only infer early electrical activity based on irregular fluctuations in basal Ca2+ (Nishii and Shibata, 2006). Given the forming heart contracts from an early stage, this raises the important question of when and how contractile activity of cardiomyocytes is first initiated during development and to what extent this influences the progression of differentiation and subsequent cardiac morphogenesis. This is especially important as the forces exerted by cardiac contractions have been shown in several models to be required for proper heart development (Granados-Riveron and Brook, 2012), and to modulate gene expression (Miyasaka et al., 2011) at later developmental stages.
In mature cardiomyocytes, coordinated electrical excitation is coupled to physical contraction in a process termed excitation contraction coupling (ECC) (Bers, 2002). ECC relies on changes in the intracellular concentration of the second messenger Ca2+ via release from the sarcoplasmic reticulum (SR) in a process termed Ca2+ induced Ca2+ release (CICR) (Fabiato and Fabiato, 1979). Increases in the concentration of intracellular Ca2+ result in cardiomyocyte contraction due to Ca2+ binding to troponin and myofilament activation. ECC involves a number of specific proteins including L-type Ca2+ channels (LTCC, sarcolemmal Ca2+ influx), ryanodine receptors (RyR2, SR Ca2+ release), the sarco (endo) plasmic reticulum Ca2+ ATPase (SERCA, SR Ca2+ uptake) and the Na+/Ca2+ exchanger (NCX, Sarcolemmal Ca2+ efflux). Targeted disruption of genes encoding ECC proteins in mice has shown that contractile activity of immature cardiomyocytes does not require ECC. Embryonic cardiomyocytes have a less developed SR and T-tubule system as well as an increased requirement for sarcolemmal Ca2+ flux (Conway et al., 2002; Seki et al., 2003) and whilst they express a variety of ion channels and exchangers present in the adult heart (Seisenberger et al., 2000; Cribbs et al., 2001; Linask et al., 2001), the expression and activity of these proteins is distinct from that in mature cardiomyocytes (Liang et al., 2010). Using isolated cells as well as genetically manipulated animals, two contrasting mechanisms have been proposed for how Ca2+ transients are generated in the developing heart from approximately E8.5 onwards. Early studies suggested that myocyte contraction is triggered by sarcolemmal Ca2+ influx through voltage activated Ca2+ channels with little or no contribution from the SR (Nakanishi et al., 1988; Takeshima et al., 1998). In contrast, more recently it has been shown that at ~E8.5–9, Ca2+ transients originate from the SR, via RyR together with InsP3 channels, to trigger electrical activity as well as contraction (Viatchenko-Karpinski et al., 1999; Méry et al., 2005; Sasse et al., 2007; Rapila et al., 2008). Whilst these studies characterised SR function at ~E8.5–9, they did not investigate how Ca2+ transients are regulated at the earliest stages of cardiac crescent development when contraction is initiated, and relied on experiments performed using isolated cells cultured for between 12 to 70 hr (Sasse et al., 2007; Rapila et al., 2008). Thus there is a lack of cellular resolution in vivo and no current mechanistic insight into the onset of Ca2+ handling and its impact on differentiation and cardiogenesis.
We report here, for the first time, high-resolution live imaging of Ca2+ transients during the earliest manifestation of murine heart development well before any indication of spontaneous cardiac contractions. We employed the use of multiple pharmacological inhibitors to address the contribution of the NCX1 and LTCC Ca2+ channels during this process and reveal an essential early role for NCX1-dependent Ca2+ handling on downstream cardiac differentiation and morphogenesis.
It is commonly stated that initiation of contraction begins with the formation of the LHT (Bruneau, 2008), and whilst cardiac contractions have been reported just prior to the ‘linear heart tube’ stage (Navaratnam et al., 1986; Nishii and Shibata, 2006; Linask et al., 2001; Kumai et al., 2000; Porter and Rivkees, 2001), a precise study on the initiation of cardiac function has not been conducted. A difficulty with these reports is the use of ‘embryonic day’ or ‘somite number’ to stage the developing heart. Somite number is variable in its correlation to the overall embryonic stage (Kaufman and Navaratnam, 1981), can depend on genetic background (Méry et al., 2005; Porter and Rivkees, 2001) and importantly, is not a sufficiently fine-grained proxy for the developmental stages of the heart. This can lead to ambiguities, as a ‘3-somite’ embryo may range from the cardiac crescent to early LHT stages. We, therefore, created a staging system specific to the early heart, from early crescent to LHT (Supplementary file 1a), similar to studies at later stages when a more precise morphological characterization is necessary (Biben and Harvey, 1997). On this basis, we defined four stages (0, 1, 2 and 3) of cardiac crescent development prior to the LHT stage, based on clear morphological differences. Stage 0 hearts represented the first discernible crescent structure situated beneath the developing head folds, being the widest (360–390 µm along the medio-lateral axis) and thinnest (70–80 µm along the rostro-caudal axis) of the crescent stages (Supplementary file 1a). Whilst stage 1 was morphologically similar to stage 0, the cardiac crescent had become narrower (300–370 µm) and thicker (75–95 µm). By stage 2, folding of the cardiac crescent is evident based on the formation of a trough at the embryonic midline and two lobes on either side. As the embryo transitions to stage 3 this trough becomes less obvious with a rostral-caudal elongation of the heart as the LHT begins to form. Transition from stage 3 to the LHT was defined by the complete fusion of the two lobes and loss of the central trough (Figure 1; Supplementary file 1a).
To molecularly characterize these stages, we performed immunostaining for three proteins of the cardiac contractile machinery: sarcomeric α-actinin (α-Act), a protein of the Z-line; Myomesin (Myom), a protein of the M-line and cardiac Troponin T (cTnT), the Tropomyosin binding subunit of the troponin complex (Figure 1; Figure 1—figure supplement 1). At stage 0, cTnT was the most evident contractile protein within the early cardiac crescent, albeit without sarcomeric banding (Figure 1—figure supplement 1A). Both α-Actinin and Myomesin appeared in small clusters of cells at stage 0 (Figure 1A). Sarcomeric banding of these proteins, indicative of contractile capability, only manifested later in discrete regions within stage 1 and 2 crescents (Figure 1B,C; Figure 1—figure supplement 1B,C). This was surprising given that the crescent stages of early heart development are thought to correspond to non-differentiated cardiac mesoderm (reviewed in Harvey, 2002), without prior reports of contractile machinery or functionality. By stage 3, sarcomere assembly and myofibrilar banding became more uniform, coincident with coalescence of the paired crescent primordia to the embryonic midline. This increased through to the linear heat tube stage, consistent with progressive cardiomyocyte maturation (Figure 1D,E; Figure 1—figure supplement 1D,E). To further characterize stage development in relation to sarcomere assembly, qRT-PCR was performed on isolated cardiac crescents, to assess the corresponding gene expression of Myom1 (encoding Myom), Actn2 (encoding α-actinin) and Tnnt2 (encoding cTnT) (Figure 1F). Myom1, Actn2 and Tnnt2 expression significantly increased between stages 0 and 1 and continued to increase until formation of the LHT (Supplementary file 1b).
Coincident with sarcomere formation at stage 1 (Figure 1B; Figure 1—figure supplement 1B), we observed the onset of beating in discrete foci in the lateral regions of cardiac crescents of cultured mouse embryos, by differential interference contrast (DIC) imaging (Video 1), significantly earlier than previously described (Navaratnam et al., 1986; Nishii and Shibata, 2006). These foci generally contracted at the same rate, indicative of either synchronization or a shared intrinsic beat rate for nascent cardiomyocytes (Figure 2—figure supplement 1). The earliest cardiac contractions had a frequency of approximately 30 beats per minute (BPM), which increased significantly by stage 3 (after approximately 5 hr) to around 60 BPM (Figure 2A). Contractile activity requires cytosolic Ca2+ flux, therefore, to investigate the earliest manifestations of Ca2+ handling within the cardiac crescent, we loaded embryos with the fluorescent Ca2+ indicator Cal-520 followed by live imaging using confocal microscopy. From stage 1 crescents until late stage 3, lateral propagation of Ca2+ transients was observed across the embryonic midline (Figure 2B), even through regions of non-contractile tissue (Video 2). As the cardiac crescent starts to fuse to form the LHT, the transients switch from a lateral to a more caudal-rostral propagation (data not shown). At stage 0 spontaneous asynchronous Ca2+ oscillations (SACOs) were observed within the forming crescent, in the absence of contractile activity and sarcomeric banding of cTnT (Figure 2C; Video 3). SACOs were observed in all stage 0 cardiac crescents imaged (n = 35), propagated within individual cells (Figure 2D’’) and displayed a range of Ca2+ dynamics with variable frequencies and durations (Figure 2D’, Video 4). Compared to Ca2+ transients at later stages (Figure 2A) SACOs were significantly slower, with fluorescence reaching peak intensity between 0.79 and 11.9 s and decreasing with a similar slow rate of efflux (Figure 2—figure supplement 1C). During a ~20 s recording period we observed only 10.3 ± 0.7 individual SACOs per embryo (n = 35) occurring in different sites. Consecutive SACOs in the same site were rarely observed within the 20 s imaging window and, therefore, we conclude that SACOs in individual cells occur at a frequency < 3 bpm. The appearance of Ca2+ transients in the embryonic heart prior to beating (Figure 2A,B) is consistent with the idea that Ca2+ signalling within early cardiac progenitors may be important to promote sufficient differentiation for subsequent contractile function (Mesaeli et al., 1999; Li et al., 2002).
We next used an embryonic stem cell (ESC)-derived model of cardiomyocyte development to complement the embryo studies and provide further insight into the stages of cardiac contraction coincident with cardiomyocyte specification and differentiation. While ESC-derived cardiogenesis is aligned with stages of mesoderm induction, pre-cardiac mesoderm, cardiomyocyte specification and differentiation based on temporal patterns of gene expression (reviewed in Kattman and Keller, 2007; Willems et al., 2009; Van Vliet et al., 2012), this has not been rigorously mapped onto embryonic stages of heart development. We, therefore, performed a principal component analysis (PCA) and hierarchical clustering of 12 cardiac related gene expression profiles of whole embryos across embryonic stages E7.5 to E8.5, compared with ESC-derived embryoid bodies (EBs) from days 0 to 7 inclusive and day 14 of differentiation. Whole embryos were used to reflect the myriad of cell types present in the ESC-cardiomyocyte differentiation assay.
Hierarchical gene clusters were evident with the onset of beating at E7.5 and day 4 and 5 of EB formation, coincident with cardiac progenitor gene expression (Figure 2—figure supplement 2A). Expression profiles by days 6 and 7 correlated with E8.0 (stage 0 to stage 2) when beating was well established in both ESC-derived EBs and the embryonic heart, whereas day 14 was equivalent to the more mature E8.5 (Figure 2—figure supplement 2A). Key cardiac genes Myh6, Tnnt2 and Mef2c revealed comparable trends of increased expression over time of differentiation in both EBs and embryos (Figure 2—figure supplement 2). The cardiac specification program, characterized by expression of Mesp1, was evident by day 4 in EBs (Figure 2—figure supplement 2I) following Brachyury expression, an indicator of mesoderm formation, and loss of pluripotency markers such as Pou5f1 (encoding Oct-4; Figure 2—figure supplement 2J–K). Mesp1 up-regulation in EBs was consistent with expression at E7.5 in the embryo (Figure 2—figure supplement 2E) and preceded beating at day 6 and 7. These later stages revealed an up-regulation of Ca2+-handling genes such as Slc8a1, Cacna1c and Ryr2 (Figure 2—figure supplement 2L–N).
Sarcomere assembly in ESC-derived cardiomyocytes accompanied the onset of beating at day 7 (Figure 2—figure supplement 3A,B) and, interestingly, the rate of beating was comparable at the outset (day 7 of differentiation) with that observed in the developing heart at stage 1 (Figure 2—figure supplement 3C), consistent with an intrinsic rate for early cardiomyocytes contractions. Furthermore, Ca2+ transients were observed in day 7 EBs as both large propagating waves (Figure 2—figure supplement 3D,F; Video 5) and within small regions of cells prior to beating, similar to that observed in the stage 0 embryonic heart (Figure 2—figure supplement 3E,G; Video 6).
ECC components, and specifically NCX1, have not previously been implicated in the initiation event of cardiac contraction, nor investigated at the earliest stages of heart development coincident with the onset of beating. We, therefore, assessed ECC gene expression on embryonic hearts at the different stages defined herein; focusing specifically on Slc8a1 (encoding NCX1), Cacna1c and Cacna1d (encoding the LTCC subunits, CaV1.2 and CaV1.3 respectively; Figure 3A), Atp2a2 (encoding SERCA2), Iptr2 (encoding InsP3 type 2 channels) and Ryr2 (encoding RyR2) that collectively are key components of SR Ca2+ regulation (Figure 3—figure supplement 1A–D; Supplementary file 1b). Between E7.75 (as defined by the presence of clear head-folds but not a cardiac crescent) and stage 0, Slc8a1 significantly increased 21 fold (p-value<0.001), whilst Cacna1c revealed a modest but non-significant increase of 2.5 fold (p-value>0.05) and Cacna1d a significant 4-fold increase (p-value <0.01). From stage 1 onwards Slc8a1, Cacna1c and Cacna1d expression continued to significantly increase until stage 3 (Figure 3A,B; Figure 3—figure supplement 1A, Slc8a1, 234-fold; Cacna1c, 38-fold; Cacna1d, 41-fold). Between stage 3 and the LHT, expression of Slc8a1 and Cacna1c was maintained whilst Cacna1d significantly decreased (Supplementary file 1b; p-value<0.05). Previous studies have suggested a non-ECC dependent role for the SR during development, implicating both InsP3 and RyR channels (Méry et al., 2005; Sasse et al., 2007; Rapila et al., 2008). While Ryr2 significantly increased 30 fold between E7.75 and stage 0 (p-value<0.001), expression of Atp2a2 only increased 1.7 fold (p-value<0.05) and Iptr2 did not significantly change (p-value>0.05; Figure 3—figure supplement 1C,D).
We performed a similar analysis on EB derived cardiomyocytes. Slc8a1 expression increased significantly in EBs prior to Cacna1c (day 2 versus day 4; Figure 3B,C) and to a much greater extent with the onset of beating (110 fold versus 38 fold; Figure 3B,C), suggesting NCX1 might play a more immediate role in the onset of beating. This was supported by the lack of any further increase in Slc8a1 expression from E9.5 through to birth (P0) and adulthood (Figure 3—figure supplement 2), whereas Cacna1c expression fluctuated across later developmental stages and significantly increased post-natally (Figure 3—figure supplement 1A,B) with increased maturation.
Since the sarcolemmal channel genes revealed the most significant increases over the developmental timecourse, we proceeded to investigate spatiotemporal protein expression of NCX1 and CaV1.2 in embryos (Figure 3D,E), and ESC-derived cardiomyocytes (Figure 3F,G). Whilst NCX1 was clearly detectable within the cardiac crescent at stage 0 (Figure 3D), CaV1.2 was absent (Figure 3E). Differences in the expression of NCX1 and LTCC prior to beating were not maintained at later stages, after established contraction (stage 2 onwards), when both channels were expressed (Figure 3H,I). In EBs at day 7 of culture, both NCX1 and CaV1.2 were expressed, but whilst NCX1 was consistently co-expressed with cTnT (Figure 3F), there were cTnT+ foci that were negative for CaV1.2 (Figure 3G). Collectively, this expression data suggests that NCX1 precedes Cav1.2 within the developing cardiac crescent at stage 0, being present prior to and at the onset of both SACOs and beating, whereas Cav1.2 became upregulated later from stage 1 onwards. Of note, while NCX1 and CaV1.2 signal was detected in other regions of the embryo, notably in the head folds, in contrast to the heart it was not membrane localised in these regions, indicative of non-functional protein. Furthermore qRT-PCR data for isolated head folds did not reveal any significant increases in Slc8a1 or Cacna1c expression, from E7.75 through to LHT stages (p-value>0.05; Figure 3—figure supplement 2E,F; Supplementary file 1c) even though the head folds were maturing, as shown by morphological changes and expression of the neural ectoderm marker Sox1 (E7.75 versus LHT, p-value<0.001; Supplementary file 1c)
To functionally assess the roles of the sarcolemmal and SR channels in establishing and maintaining heartbeat, we employed pharmacological blockade on embryos maintained ex-vivo and ESC-derived cardiomyocyte cultures. We inhibited NCX1 using the specific inhibitors CB-DMB (Secondo et al., 2009) or KB-R7943 (Kimura et al., 1999), the LTCC using nifedipine (McDonald et al., 1994) and Ryanodine together with 2-APB to simultaneously block RyR and InsP3, similar to that described previously (Sasse et al., 2007; Rapila et al., 2008). Treated embryos were imaged for contractile activity by DIC imaging and Ca2+ transients were recorded in parallel with confocal fluorescence imaging of Cal-520. Acute treatment (for a maximum of 30 min) with NCX inhibitors (CB-DMB and KB-R7943) or LTCC inhibitor (Nifedipine), affected the embryos in a stage dependent-manner (Figure 4). Both NCX1 and the LTCC were required for Ca2+ transients during stages 1 and 2 (Figure 4A), and their inhibition led to an initial confinement of Ca2+ transients to one side of the crescent (within approximately 5 min of treatment, which persisted through to 15 min) followed shortly afterwards by complete loss of Ca2+ signal (Figure 4C,D). At stage 3 and later, only the LTCC was required for Ca2+ transient generation (Figure 4B). Whilst NCX1 can function in both forward (Ca2+ efflux from the cell) and reverse (Ca2+ influx into the cell) modes, our data suggested that NCX1 in the early cardiac crescent was functioning in reverse mode, as KB-R7943, that is reported to specifically inhibit reverse mode NCX1 function (Hoyt et al., 1998; Iwamoto, 2004), recapitulated the results with CB-DMB and acted as a control for off-target effects of the latter. These data suggests that reverse mode NCX function may contribute to Ca2+ transient generation at the earliest stages of cardiac contraction, potentially via inward Ca2+ flux. The inhibitor experiments were repeated on day 7 and day 14 EBs. The relative effects of CB-DMB, KB-R7943 and nifedipine were consistent with those observed in stages 1 and 2 of the embryonic heart (Figure 4E–G). Treatment with Ryanodine + 2-APB only affected more mature embryos that had already undergone both cardiac looping and embryonic turning (Figure 4—figure supplement 1A) and did not prevent Ca2+ transients within cardiac crescents at stage 3 (Figure 4—figure supplement 1B). This suggest that a functional SR is only required once cardiac looping has been fully initiated, more than 18 hr later than the first observable SACOs within the cardiac crescent.
Taking into account the earlier upregulation of NCX1 relative to Cav1.2 at stage 0 (Figure 3A), we tested the possibility that NCX1 might be pivotal in initiating the SACOs observed in the early cardiac crescent (Figure 2C). Treatment of stage 0 embryos with CB-DMB and KB-R7943 resulted in a 90% decrease in the number of cells with SACOs after drug application when compared to baseline. This was significantly greater than following application of nifedipine to inhibit LTCC, or the DMSO control (CB-DMB, 90% inhibition + 6.6, mean + SEM, n = 10 embryos, p-value <0.01; KB-R7943, 91% inhibition + 7.0, n = 9 embryos, p-value <0.001; nifedipine, 39% inhibition + 11.4; n = 8 embryos, p-value=0.44; DMSO, 29% inhibition + 7.6, n = 10; Figure 4H–J; Supplementary file 1d). These data suggest that NCX1 is required for establishing the earliest pre-contractile SACOs.
Chronic treatment of Eomes-GFP ESC cultures (ESCs containing a knock-in of a GFP reporter into the endogenous Eomes locus (Arnold et al., 2009); marking nascent mesoderm (Ciruna and Rossant, 1999), with CB-DMB or Nifedipine, from days 0 to 14 of differentiation, resulted in a reduction in the percentage of beating EBs at day 14, down to 22% and 52% (Percentage beating EBs; DMSO, 76.53% (n = 196); CB-DMB, 22.37%, p-value<0.001 (n = 152); Nifedipine, 52.11%, p-value<0.001 [n = 71]) in the presence of CB-DMB and nifedipine respectively, compared to controls (Figure 5A), whilst not effecting cell number (Figure 5—figure supplement 1A–C). The reduction in beating EBs was supported by a down-regulation of key cardiac genes Myh6 (mean+ SEM: 0.57 ± 0.058; p-value<0.05; n = 6; Figure 5B) and Tnnt2 (0.66 ± 0.095; p-value<0.05; n = 6; Figure 5B) specifically following treatment with CB-DMB relative to control DMSO treatment. The decrease in cardiac gene expression associated with CB-DMB treatment could be observed from day 4 of Eomes-GFP ESC differentiation, at the initiation of cardiomyocyte differentiation (Figure 5—figure supplement 1D–N). In an Nkx2.5-EGFP ESC line (ESCs containing a vector expressing eGFP under the control of a murine Nkx2.5 promoter and regulatory region; marking cardiac progenitor cells [Wu et al., 2006]) this was associated with loss of GFP+ cardiac progenitors by day 14 (Figure 5—figure supplement 2A–E) and the significant down-regulation of key cardiac markers following treatment with CB-DMB relative to control DMSO treatment (Figure 5—figure supplement 2F). Importantly not all cardiac genes were effected by chronic exposure to the channel inhibitors including Slc8a1, Cacna1c and Camk2d downstream of Ca2+ signalling (Figure 5—figure supplement 3A), suggesting that the inhibitors did not simply have a global negative effect on gene expression or cardiomyocyte survival.
Given the proposed role for inward Ca2+ via NCX1, we cultured ESCs in media containing reduced concentrations of Ca2+ (0.1 mM and 1.0 mM) relative to the normal level of 1.8 mM (Figure 5C). At the end of the differentiation protocol (14 days) we accessed the percentage of beating EBs after returning to media with normal levels of Ca2+ for 2 hr. Culture in 0.1 mM Ca2+ resulted in an inhibitory effect on EB beating to the same extent (percentage beating EBs; 1.8 mM, 78.38%, n = 74; 0.1 mM, 28.75%, n = 80; p-value<0.001) as with CB-DMB treatment (Figure 5C) and culture in 1.0 mM resulted in an equivalent inhibitory effect to that following treatment with nifedipine (Figure 5C; 1.0 mM, p-value<0.01; n = 61). This suggested that influx of external Ca2+ is required for cardiomyocyte maturation/beating and supports a potential role for NCX1 working in reverse mode to bring Ca2+ into early cardiac progenitors.
We next investigated whether Ca2+ handling prior to, and concurrent with, the earliest contractile function impacted on known Ca2+-signalling pathways to activate foetal gene expression, as has been reported during adult pathological hypertrophy (Molkentin et al., 1998). Calmodulin-dependent kinase II (CaMKII) is a key component of Ca2+ and calcineurin signalling which directly impacts on downstream hypertrophic gene expression by induction of Mef2c (Wu et al., 2006; Molkentin et al., 1998; Passier et al., 2000; Zhang, 2007). Following CB-DMB-induced NCX1 inhibition at day 7 of EB differentiation, activated phospho-CaMKII (pCaMKII) levels were significantly reduced compared to either DMSO control or nifedipine treatment (mean ± SEM: DMSO, 1.18 ± 0.13; CB-DMB, 0.69 ± 0.15; nifedipine, 1.13 ± 0.06. DMSO vs. CB-DMB, p-value<0.01; CB-DMB vs. nifedipine, p-value<0.05; n = 3; Figure 5D,D'). NCX1 inhibition at day 4, a stage prior to cardiac progenitor specification, had no effect on pCaMKII levels (Figure 5—figure supplement 3B,B'). NCX1 inhibition reduced Ca2+ influx and decreased activation of CaMKII accompanied by significantly reduced expression of Mef2c and Myh7 relative to DMSO control (mean ± SEM: Mef2c, 0.71 ± 0.13; Myh7, 0.55 ± 0.18; p-value<0.05; n = 6) which, whilst previously associated with pathological cardiac hypertrophy, contribute here towards (physiological) cardiomyocyte differentiation (Figure 5B). In contrast, nifedipine treatment resulted in decreased Myh7, whereas Mef2c remained unaffected at early stages (Figure 5B).
To determine the effect of NCX1 blockade on the subsequent development of the heart, we cultured embryos isolated at E7.25 (the onset of head fold formation and pre-cardiac crescent stage) in the presence of DMSO, CB-DMB or Nifedipine for 12 hr (Figure 5E). Whilst the embryos remained viable during the culture period, initiation of heart development was impaired in those treated with CB-DMB compared to DMSO controls (Figure 5E). This was in contrast to treatment with Nifedipine alone, in which the crescent developed normally and progressed to an equivalent stage as DMSO treated embryos (Figure 5E). More specifically embryos cultured in the presence of CB-DMB had reduced expression of cTnT compared to embryos cultured in other conditions. However, most cells were still positive for Nkx2.5, suggesting delayed or impaired differentiation likely accounted for the failure of crescent formation under conditions of NCX1 blockade. The relative effects of NCX1 and LTCC inhibition on developmental progression and crescent formation were supported by corresponding gene expression data from cultured embryos (Figure 5F,G). While Tnnt2 was down-regulated in both CB-DMB and Nifedipine treated embryos, Nkx2.5 was only down-regulated in CB-DMB treated embryos (Figure 5F,G). Equally Slc8a1, was down-regulated exclusively in the presence of CB-DMB (Figure 5—figure supplement 3C), whereas Cacna1c was unaltered in the presence of either inhibitor (Figure 5—figure supplement 3C,D). These data collectively support a role for NCX in cardiomyocyte differentiation and crescent formation.
Previous studies have attempted to investigate how cardiac function develops within the early embryo. Whilst these studies are informative they rely on the dissociation and culture of embryonic cardiomyocytes to facilitate physiological measurements resulting in the loss of critical spatial and temporal information regarding Ca2+-handling and downstream changes in gene expression and morphology. Using a staging method based on morphological landmarks (stages 0–3), we characterized in detail the in vivo progression of physiological activity during early heart development. The stage series defined correlates with gradual expression of several cardiac related genes and sarcomere assembly. We observed spontaneous asynchronous Ca2+ oscillations (SACOs) at stage 0 in the developing cardiac mesoderm, before any detectable cardiac contractions. These transients appeared sporadically in individual cells within the forming cardiac crescent and did not appear to be synchronized. At stage 1, periodic Ca2+ transients began to be propagated laterally through the cardiac crescent, and traversed the midline of the crescent where there were no visible contractions. This was a rapid and dynamic process occurring through stages 0–3 that involved sarcolemmal ion channel and exchanger function. NCX1 was exclusively required for SACOs at stage 0, whereas both NCX1 and LTCC appeared to play equally important roles at stage 1 and 2. NCX1 was no longer required from stage 3 onwards when the LTCC channels maintained Ca2+ transients. We observed no contribution of the SR in regulating Ca2+ transients within the cardiac crescent, as assessed by simultaneous blockade of RyR2 and InsP3. However, consistent with previous studies (Sasse et al., 2007; Rapila et al., 2008), our data did show that the SR becomes functional at later stages during cardiac looping (~E8.5). This may represent a period in which SR Ca2+ filling is required before a threshold for Ca2+ release from the SR can occur, as has been proposed in the adult setting (Stokke et al., 2011). Overall our data reveals that during the time frame from the earliest cardiac morphogenesis (crescent maturation) to looping of the heart (approximately 18 hr) there is a rapid transition in the mechanism by which the intracellular concentration of Ca2+ is elevated, based on distinct channel and exchanger function.
The observation of spontaneous asynchronous calcium oscillations (SACOs) within the forming cardiac crescent was a surprising finding that, to the best of our knowledge, has not previously been reported in any type of excitable cell. The specific role of SACOs is currently unknown and we hypothesise that they are required in cells that need to optimally activate Ca2+-dependent signalling (via the CAMKII pathway) in order to up-regulate genes necessary for further differentiation and morphogenesis. This would explain why SACOs are present much earlier than complete sarcomere assembly. An alternative hypothesis is that SACOs are a by-product of cells that are already committed to specific cardiac lineages and, therefore, arise with the expression of specific channels required for future function. This could explain the variation in duration and frequencies of SACOs observed within the same embryo. At this point, quite how SACOs become synchronised transients is unknown. We speculate that release of a Ca2+-dependent signal from a 'pacemaker' cell may entrain neighbours to have synchronised transient periodicity. To this end we observed highly variable Ca2+ periodicity but also regions containing cells of similar periodicity (Video 2). Since blockade of NCX1 prior to the formation of the cardiac crescent, and chronic treatment in ESCs, leads to impaired cardiac differentiation it is also possible that SACOs may be present in mesoderm cells earlier than reported here, which we were not able to image due to the limitations of the current experimental set-up.
In the embryonic heart, Ca2+ handling is assigned to sequential roles for the NCX and LTCC channels, whereby NCX has been assumed to compensate, at least in part, for the rudimentary (non-functional) SR in the developing mouse heart (Conway et al., 2002). In zebrafish embryos it has recently been demonstrated that Ca2+ handling and not contraction per se is essential for regulating cardiomyocyte development (Andersen et al., 2015). Previous studies characterised functional expression of NCX from E8.5-E9.5 (post-LHT formation) in mouse (Linask et al., 2001; Reppel et al., 2007) coincident with cardiac looping and significantly later than the onset of the first heat beat described herein. NCX1 knock-out mice have been generated by multiple groups, with conflicting results in regards to the phenotype, extent of mutant heart development and the stage at which embryonic lethality occurs (Wakimoto et al., 2000; Koushik et al., 2001; Reuter et al., 2002; Cho et al., 2003). This suggests that loss of NCX1 may be compensated for at the level of early cardiomyocyte specification, differentiation and contraction. In mammals there are three different Na+-Ca2+ exchangers (NCX1, NCX2 and NCX3), and it has been previously demonstrated that these three exchangers share similar physiological properties (Linck et al., 1998; Lytton, 2007). Furthermore, NCX1 has several splicing variants with exon 1 being mutually exclusive to exon 2 (Lytton, 2007; Quednau et al., 1997). It is, therefore, possible that either a different NCX or an alternative splice variant will compensate for loss of the NCX1 variant targeted in the previous studies. Indeed, in all of the previous NCX1 generic loss-of-function studies, mutant mice were created by targeting exon 2, supporting the possibility that an alternately spliced variant may be able to compensate. Furthermore, precedent for genetic ablation being compensated for over the course of development exists, whereby patterning defects were muted over time (Bloomekatz et al., 2012). In contrast, our use of pharmacological channel blockers CB-DMB and KB-R7943, resulted in an acute stage-specific-loss of NCX1 function which attributed an essential role for NCX1 in generating SACOs, and potentially acting as a trigger to establish the onset of beating in the cardiac crescent and subsequent cardiomyocyte differentiation and morphogenesis. These findings are consistent with the situation in tremblor (tre) zebrafish which have a mutation in NCX1 leading to absence of normal calcium transients and cardiac fibrillation (Langenbacher et al., 2005) as well as earlier findings in rodents demonstrating a requirement for elevated cytoplasmic calcium to drive cardiac myofibrillogenesis in developing cardiomyocytes (Webb and Miller, 2003).
Parallel analyses on ESC-derived cardiomyocytes revealed that lowering the concentration of Ca2+ in the media had a similar effect on reducing the number of beating EBs as treatment with CB-DMB. This both reinforced the relative importance of NCX1 and also provided the first indication that the exchanger may be working in reverse mode, facilitating inward Ca2+ as necessary for cardiomyocyte differentiation. Furthermore, our use of the inhibitor KB-R7943, previously reported to specifically inhibit reverse mode NCX1 activity (Brustovetsky et al., 2011), replicated observations made with CB-DMB, such that at stage 1 and 2 both LTCC and NCX1 are required for sufficient Ca2+ influx. Whilst inhibition of NCX1 clearly blocked SACOs in stage 0 cardiac crescents, the mechanism by which NCX1 alone could lead to periodic oscillations in Ca2+ is still unclear, and may require oscillations in other ions, such as Na+, and/or contribution of other sarcolemmal proteins, such as the Plasma membrane Ca2+ ATPase (PMCA), to regulate Ca2+ efflux while NCX1 is working in reverse mode. Due to the slow nature of SACOs, oscillations in energy production along with adenosine triphosphate levels could also be involved in SACO generation, especially with reduced SR function. Whilst SR inhibition did not prevent stage 3 Ca2+ transients, we have not tested the involvement of SR function at stage 0 and, therefore, cannot fully exclude that periodic Ca2+ releases from the SR are involved in the generation of SACOs. The latter has been reported in cultured E8.5–9 embryonic cardiomyocytes as a pace making mechanism (Sasse et al., 2007; Rapila et al., 2008) at later stages than were the focus in this study. To further understand the mechanism of NCX1 in SACO generation will require in vivo electrophysiological analysis to more accurately determine whether the inhibitory effect of NCX1 blockade with CB-DMB and KB-R7943 is due to effects on reverse mode NCX1 function (inhibition of translemmal Ca2+ influx) or forward mode NCX1 function (inhibition of Ca2+ efflux leading to Ca2+ overload), imbalance of Ca2+ homeostasis or off-target effects. Although the existence of the NCX1 acting in reverse mode is contentious, and the precise function of KB-R7943 is still debated in the field, it is difficult to otherwise explain how inhibition of NCX1 can block SACOs. That said, regardless of mode of action, the observation that at stage 0 SACOs were abolished with both CB-DMB and KB-R7943 treatment, but persisted when treated with nifedipine, suggests that NCX1, and not the LTCC, plays a major role in Ca2+ transient generation within the early cardiac crescent.
As cardiomyocytes matured, transition to LTCC became the predominant mechanism for inward Ca2+ entry, as demonstrated by nifedipine-induced inhibition of beating at later stages in both the embryo and ESC-derived cardiomyocytes. NCX1 expression was further maintained at high levels during more advanced stages (stage 0-LHT), suggesting a later role in ensuring Ca2+ removal via its forward mode of action. Of note, the early versus late roles for mammalian NCX1 and LTCC, respectively, are further supported by studies on tre zebrafish, whereby sarcomeric assembly defects in developing cardiomyocytes following loss of NCX1 function are not recapitulated by mutations in LTCC (Ebert et al., 2005). Increased expression of NCX1 has also been linked with pathological hypertrophy and heart failure (reviewed in Sipido et al., 2002), whereby elevated NCX1 is thought to compensate for defective ECC and depressed function of SERCA but also produce arrhythmogenic-delayed after-depolarisations (Gómez et al., 1997; Schultz et al., 2004; Venetucci et al., 2007). Transgenic mice over-expressing NCX1 within the myocardium exhibited a proportional decrease in contractile function and increased incidence of heart failure, suggesting a decompensatory mechanism with regards to Ca2+ handling (Roos et al., 2007).
Delta isoforms of CaMKII predominate in the heart and are involved in multiple signalling cascades to regulate gene expression, as well as cardiomyocyte physiology including Ca2+ and Na+ homeostasis (Wagner et al., 2006; Aiba et al., 2010). In this study, CaMKII activation was impaired following NCX1 inhibition in embryonic stem cells, and, moreover, canonical hypertrophy genes, including Mef2c and Myh7 were down-regulated in response to impaired NCX function during development. Whilst changes in gene expression did differ between embryos and ESCs in response to treatment with different drugs, this likely reflects inherent differences between the in vitro versus in vivo models, as well as the timing and length of drug exposure. ESCs were exposed at a relatively earlier stage of cardiac lineage specification and for longer periods, which was not feasible in the live embryo cultures, resulting in a stronger down-regulation of the genes investigated. Overall though these findings suggest analogous roles for NCX1 in early heart development and adult hypertrophy, with regards Ca2+-handling and foetal cardiac gene induction to promote physiological or pathological myocyte growth, respectively.
There is recent precedent for a role for Ca2+ in the establishment of other embryonic lineages; most notably Ca2+ signals are involved in the earliest steps of neurogenesis, including neural induction and the differentiation of neural progenitors into neurons (Leclerc et al., 2012). Here we show that pharmacological inhibition of NCX1 and dysregulation of Ca2+ handling from the outset had an adverse effect on early cardiomyocyte differentiation and led to impaired cardiogenesis in the embryo (Figure 5). Thus, an early induction of Ca2+-handling preceding beating within cardiac muscle is pivotal for subsequent terminal differentiation and normal heart development.
All animal experiments were carried out according to UK Home Office project license PPL 30/3155 and 30/2887 compliant with the UK animals (Scientific Procedures) Act 1986 and approved by the local Biological Services Ethical Review Process. To obtain wild-type embryos C57BL/6 males (in house) were crossed with CD1 females (Charles River, England). All mice were maintained in a 12-hr light-dark cycle. Noon of the day finding a vaginal plug was designated E0.5. In order to dissect the embryos the pregnant females were culled by cervical dislocation in accordance with the schedule one of the Animal Scientific Procedures Act. Embryos of the appropriate stage were dissected in M2 medium (Sigma-Aldrich, England).
Progressive crescent stages were defined based on morphological criteria: the length (medio-lateral axis) and the maximum height (rostral-caudal axis) of the cardiac crescent was measured for each embryo. Embryos were considered to be at the LHT stage once both sides of the cardiac crescent were completely folded and fused. The ratio between width and maximum height measurements (µm) was used to categorize the embryos from stage 0 through to stage 3 (Supplementary file 1a).
Live imaging of embryos, including Ca2+ imaging was performed as previously described, with some adaptations (Chen et al., 2014). Briefly, freshly dissected embryos were imaged in a mix of 50% phenol red-free CMRL (PAN-Biotech, Germany) supplemented with 10 mM L/glutamine (Sigma-Aldrich) and 50% Knockout Serum Replacement (Life Technologies, England). Initial characterisation of cardiac contractions was performed using Differential Interference Contrast (DIC) imaging on a Spinning Disk Confocal microscope at 37°C and an atmosphere of 5% CO2 + Air. Images were acquired at 10 frames per second (fps) for up to 20 s. For all experiments involving Ca2+ imaging, embryos were loaded with 8 μM of Cal-520 by incubating the embryos in 50% CMRL + 50% Knockout Serum Replacement with the dye for 15 min at 37°C and an atmosphere of 5% CO2 + Air. The embryos were then transferred to fresh media in a MatTek dish (MatTek Corporation, Framingham, MA) without the dye and imaged. To image Ca2+ transients in embryoid bodies (EBs), ESCs were cultured in hanging drops in MatTek dishes for four days under differentiation conditions. At day 7, the cells were loaded with 8 μM Cal-520 for 30 min in media without serum at room temperature and then transferred into media with serum and cultured in the presence of the dye for 10 min at 37°C and an atmosphere of 5% CO2 + Air. All Ca2+ imaging was performed with a Zeiss 710 LSM fitted with an environmental chamber to maintain the embryos at 37°C at 5% CO2. Embryos were imaged with a 20× air objective (0.6 NA) with a single optical section every 97 ms (~10 frames per second). Images were captured at 256 × 256 pixel dimensions, with a 2× line step and no averaging to increase the scan speed. For acute inhibition of Ca2+ transients in embryos (stage 1 to LHT) and EBs, Ca2+ transients were first imaged at baseline, drug containing media was then added and imaging was performed at 5, 15 and 30 min post drug treatment. Inhibition was defined as the complete cessation as well as confinement of Ca2+ transients to small regions of the cardiac crescent. For inhibitor experiments involving stage 0 embryos, imaging was carried out at baseline, 5 and 15 min post treatment. For all the experiments involving calcium imaging of embryo the overlying yolk sac endoderm had to be dissected out in order to allow proper drug and dye penetration, as well as better visualisation of the cardiac mesoderm. For experiments involving embryos Nifedipine (Sigma-aldrich) was used at a final concentration of 10 μM, CB-DMB (Sigma-aldrich) at 20 μM, KB-R7943 (Sigma-aldrich) at 30 μM, Ryanodine (Tocris Bioscience, England) at 100 μM and 2-APB at 200 μM, all diluted in DMSO (Sigma-aldrich). We found that most drugs had to be used at a higher concentration than previously used in studies involving isolated cells, presumably due to penetration difficulties inherent with using whole embryos. Control experiments for Nifedipine, CB-DMB and KB-R7943 were performed with 0.002% DMSO, and for experiments involving dual inhibition with Ryanodine + 2-APB with 0.6% DMSO. All experiments involving embryos were repeated with at least three different litters (6–10 embryos). Both embryo and ESC experiments were performed on at least three independent days.
Embryos were cultured in the presence of drug (CB-DMB or nifedipine) for 12 hr, from E7.5 to E8.0 using a rolling culture system. Embryos were cultured in a mix of 50% CMRL and 50% Knockout Serum Replacement at 37°C and with an atmosphere of 5% CO2+ Air. Only embryos at E7.5, prior to cardiac crescent and head fold formation were cultured. For these experiments embryos were cultured in the presence of either in 10 μM Nifedipine, 3 μM CB-DMB or 0.0003% DMSO. Experiments for immunostaining were performed on three independent days, while experiments for qRT-PCR were performed on four different days for Nifedipine treatments and five days for CB-DMB treatments.
Cardiomyocyte differentiation from ESCs was carried out as previously described using an Nkx2.5-GFP (Moretti et al., 2006) and Eomes-GFP (Arnold et al., 2009) cell line. Briefly, ESCs were maintained in an undifferentiated state by culturing with KO-DMEM (Gibco, England) supplemented with glutamax (2 mM; Gibco), embryomax FBS (15%; Millipore), nonessential amino acids (0.1 mM; Invitrogen, England), penicillin (60U/mL; Gibco), streptomycin (60 μg/mL; Gibco), β-mercaptoethanol (0.1 mM; Sigma-aldrich) and Leukaemia inhibitory factor (1000 U/ml; Millipore, England). Cardiomyocyte differentiation was induced using the hanging drop culture method (Kattman and Keller, 2007). Approximately 500 ESCs were plated in 20 μl drops of differentiation media (4.5 g glucose/DMEM, embryomax FBS (20%), nonessential amino acids (0.1 mM), penicillin (60 U/ml), streptomycin (60 μg/ml), β-mercaptoethanol [0.1 mM]) on the lids of petri dishes and cultured as hanging drops throughout the first four days of differentiation, allowing embryoid bodies (EBs) to form. At day 4, the EBs were transferred onto 0.1% gelatin coated plates for a further 10 days of culture before being collected at day 14 of differentiation. 1 μM CB-DMB and 10 μM Nifedipine were added to the differentiation media at day 0. For control experiments, DMSO was added at the same concentration as drug containing media. Once the EBs had been plated at day 4, drug-containing media was changed every two days up until day 14. To assess the percentage of EBs which were beating, drug containing media was removed 2 hr prior to assessment and replaced with fresh drug-free culture media. Culturing of ESCs in different Ca2+ concentrations was achieved using Ca2+ free DMEM (Gibco) with Ca2+ being added back to the desired concentration (0.1 mM, 1.0 mM, 1.8 mM). For immunostaining, ESCs were cultured on 0.1% gelatin coated glass coverslips before being fixed with 3.7% PFA for 30 min on ice. For RNA isolation tissue samples were dissociated for 2 min using 0.25% trypsin-EDTA at 37°C prior to snap freezing.
Dissected embryos were fixed for 1 hr at room temperature with 4% PFA in PBS. The embryos were then washed 3x in PBT-0.1% (PBS with 0.1% Triton X-100) for 15 min, permeabilised in PBT-0.25% for 40 min and washed again 3x in PBT-0.1%. The embryos were transferred to blocking solution (5% donkey serum, 1%BSA in PBT-0.1%) overnight (o/n) at 4°C. Primary antibodies (Supplementary file 1e) were then added to the solution and incubated o/n at 4°C. The embryos were washed 3x in PBT-0.1% and incubated o/n 4°C in PBT-0.1% with the secondary antibodies (Supplementary file 1e), then subsequently washed 3x PBT-0.1% for 15 min and mounted in Vectashield mounting media with DAPI for at least 24 hr at 4°C. After fixation ESC samples were rinsed with PBS before being permeabilised with PBT-0.1% for 10 min, followed by blocking with 10% goat serum, 1% BSA in PBT-0.1% for 1 hr. Incubation with primary antibodies, diluted in blocking buffer, was carried out o/n at 4°C. After incubation with primary antibodies samples were washed for 3x for 10 min with PBT-0.1% and then incubated with secondary antibodies (Supplementary file 1e) diluted in blocking buffer for 1 hr at room temperature. After incubation with secondary antibodies samples were washed 5x for 5 min in PBS. Samples were mounted using Vectashield mounting media with DAPI for at least 24 hr prior to imaging with either a 40x oil (1.36 NA) or water (1.2 NA) objective. Images were captured at a 512 × 512 pixel dimension and tiled 2x2 with a Z-step of 1.5 µm. For embryos each staining was repeated for at least three litters (6–10 embryos per litter). Both experiments involving embryos and ESCs were performed on at least three independent days and with two different secondary antibodies.
RNA extraction of whole embryos, embryonic hearts, head folds and ESC samples was performed using an RNeasy Micro Kit (Qiagen, England) according to manufacturer’s instructions: briefly, homogenisation was carried out with a 21G needle and the extract run through an on-column DNase I treatment. For P0 and adult heart samples, RNA extraction was performed using Trizol (Invitrogen, England), according to the manufacturer’s instructions, additional DNase I (Promega, England) treatment on Trizol-extracted RNAs was carried out to eliminate genomic DNA contamination. In order to collect enough RNA for isolated cardiac crescent and head fold development, each biological replicate was composed of 10 individual cardiac crescents or head folds. For both types of extraction, RNA pellets were dissolved in RNase-free water and the RNA quality and quantity determined by Nanodrop readings at 260, 280 and 230 nm wavelengths. cDNA was generated from 1 μg of RNA using random primers and SuperScript III polymerase (Invitrogen). The expression of mRNAs for genes of interest (Supplementary file 1f), together with endogenous controls (treated embryos and differentiated ES cells, HPRT, GAPDH, 18 s; in vivo timecourse, GAPDH & HPRT; ES cell differentiation, GAPDH & 18 s (Murphy and Polak, 2002) were measured in triplicate for each sample by quantitative real-time PCR using SYBR Green (Applied Biosystems, England). Each reaction contained: 8 ng cDNA, 0.5 μl of each primer, 6.5 μl water and 12.5 μl 2 x SYBR Green, made up with H2O to a final volume of 22 μl. Primers (Sigma-aldrich) were either designed using Primer-BLAST (National Center for Biotechnology Information, National Institutes of Health) or obtained from PrimerBank (http://pga.mgh.harvard.edu/primerbank; Primer 3) or previous publications (primer sequences in Supplementary file 1f). Primers were designed to span exon-intron boundaries, have annealing temperatures around 60°C and generate amplicons between 50–200 bp. The reaction mixture and samples were loaded into either a MicroAmp Optical 96-Well Reaction Plates or MicroAmp Fast Optical 96-Well Reaction Plates and sealed with Optical Adhesive Films (Life Technologies). Quantification was performed on a ViiA 7 Detection System (Applied Biosystems) using a PCR programme of 95°C 15 min followed by 40 cycles of (95°C 15 s melting phase and 60°C 1 min annealing and extension). Amplification of a single amplicon was confirmed by obtaining dissociation curve (melt curve) profiles as well as using gel electrophoresis to separate the reaction product. Cycle threshold (Ct) values were generated using either Viia7 software (Applied Biosystems). Relative gene expression levels were obtained using the ΔΔCt method, in which expression of each gene of interest was normalised to endogenous controls (Schmittgen and Livak, 2008) (Murphy and Polak, 2002), and presented as fold change over a reference sample. For time course data fold-change was calculated in relation to the earliest stages (E7.75 in vivo, D0 ESC models), whilst for drug treated experiments fold change was calculated relative to control (DMSO) samples. Non-template controls were performed by replacing cDNA with water, to test for non-specific amplification.
Protein was extracted on ice using direct lysis of cells with NP-40 extraction buffer (150 mM NaCl, 1.0% NP-40, 50 mM Tris (pH8.0)) and 1x protease and phosphatase inhibitor cocktail (Roche, England). Lysates were span at 10,000 rpm for 20 min at 4°C and supernatant collected. An aliquot was taken for protein quantification using a DC protein assay (Bio-rad, England). Supernatants were prepared for SDS-PAGE with the addition of 4x Laemmli sample buffer and boiling at 95°C for 5 min. Western blotting was performed using standard SDS-PAGE methods using HRP-conjugated secondary antibodies and enhanced chemiluminescence detection (GE Healthcare, England).
All data involving beat rate and qPCR gene levels was compared using one-way ANOVA followed by a Tukey test for multiple comparisons. In cases where the raw data failed to map to a normal distribution with consistent variance, we applied Taylor’s law to choose the best transformation for the data. All data to be analysed passed the Shapiro-Wilk normality test and Bartlett test for homogeneous variances. To compare the number of affected embryos upon acute treatments, a Freeman-Halton extension of Fisher exact probability test was applied due to a smaller number of samples. To compare the effect of different treatments on the number of beating EBs, due to a large number of samples, a Chi Square test with a Bonferroni correction for multiple comparisons was performed instead. Principal Component Analysis (PCA) was carried out to directly compare temporal gene expression data from EBs with that derived from embryos; each biological replicate for embryonic stage was composed of 5–6 embryos and for EBs was composed of 10–80 EBs, depending on the day of differentiation. The data from each sample was normalized by assessing the ratio with the maximum value of all samples. A log transformation was applied to the normalized data and the principal components were calculated using R environment. The 3D representation of the PCA was constructed by plotting the 3 first components given that these explained more that 95% of the observed variance. A hierarchical clustering analysis was performed using Ward’s minimum variance method as a more precise clustering algorithm to divide the samples in different groups (Ward, 1963).
A variant of absolute image filter was used to visualize and plot measurements of cardiac contractions in the developing cardiac crescent as described elsewhere (Chen et al., 2014). Briefly, pixel displacement, indicative of contractions, was visualized and represented by increased grey levels within the crescent. Change in pixel intensity was assessed in a selected region, to reveal the contraction dynamics. Background Ca2+ signal was subtracted from all frames of a given time-lapse using ImageJ. To obtain the profiles for Ca2+ transients, regions of interest were plotted using the ratio between observed fluorescent and minimum fluorescent (F/F0) after background subtraction.
Calcium signaling regulates ventricular hypertrophy during development independent of contraction or blood flowJournal of Molecular and Cellular Cardiology 80:1–9.https://doi.org/10.1016/j.yjmcc.2014.12.016
Building the mammalian heart from two sources of myocardial cellsNature Reviews Genetics 6:826–837.https://doi.org/10.1038/nrg1710
Partial rescue of the Na+-Ca2+ exchanger (NCX1) knock-out mouse by transgenic expression of NCX1Experimental & Molecular Medicine 35:125–135.https://doi.org/10.1038/emm.2003.18
Expression of the T-box gene Eomesodermin during early mouse developmentMechanisms of Development 81:199–203.https://doi.org/10.1016/S0925-4773(98)00243-3
Role of sodium-calcium exchanger (Ncx1) in embryonic heart development: a transgenic rescue?Annals of the New York Academy of Sciences 976:268–281.https://doi.org/10.1111/j.1749-6632.2002.tb04749.x
Identification of the t-type calcium channel (Ca(v)3.1d) in developing mouse heartCirculation Research 88:403–407.https://doi.org/10.1161/01.RES.88.4.403
The impact of mechanical forces in heart morphogenesisCirculation: Cardiovascular Genetics 5:132–142.https://doi.org/10.1161/CIRCGENETICS.111.961086
Forefront of Na+/Ca2+ exchanger studies: molecular pharmacology of Na+/Ca2+ exchange inhibitorsJournal of Pharmacological Sciences 96:27–32.https://doi.org/10.1254/jphs.FMJ04002X6
Specification of multipotential cardiovascular progenitor cells during embryonic stem cell differentiation and embryonic developmentTrends in Cardiovascular Medicine 17:240–246.https://doi.org/10.1016/j.tcm.2007.08.004
Early differentiation of the heart in mouse embryosJournal of Anatomy 133:235–246.
Direction-independent block of bi-directional Na+/Ca2+ exchange current by KB-R7943 in guinea-pig cardiac myocytesBritish Journal of Pharmacology 128:969–974.https://doi.org/10.1038/sj.bjp.0702869
Loss of connexin45 causes a cushion defect in early cardiogenesisDevelopment 127:3501–3512.
The calcium: an early signal that initiates the formation of the nervous system during embryogenesisFrontiers in Molecular Neuroscience 5:3.https://doi.org/10.3389/fnmol.2012.00064
Calreticulin reveals a critical Ca(2+) checkpoint in cardiac myofibrillogenesisJournal of Cell Biology 158:103–113.https://doi.org/10.1083/jcb.200204092
Electrophysiological basis of the first heart beatsCellular Physiology and Biochemistry 25:561–570.https://doi.org/10.1159/000315075
Functional comparison of the three isoforms of the Na+/Ca2+ exchanger (NCX1, NCX2, NCX3)The American Journal of Physiology 274:C415–C423.
Na+/Ca2+ exchangers: three mammalian gene families control Ca2+ transportThe Biochemical Journal 406:365–382.https://doi.org/10.1042/BJ20070619
Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cellsPhysiological Reviews 74:365–507.
Heartbeat regulates cardiogenesis by suppressing retinoic acid signaling via expression of miR-143Mechanisms of Development 128:18–28.https://doi.org/10.1016/j.mod.2010.09.002
Initiation of embryonic cardiac pacemaker activity by inositol 1,4,5-trisphosphate-dependent calcium signalingMolecular Biology of the Cell 16:2414–2423.https://doi.org/10.1091/mbc.E04-10-0883
Differentiation of the myocardial rudiment of mouse embryos: an ultrastructural study including freeze-fracture replicationJournal of Anatomy 146:65–85.
Mode and determination of the initial contraction stage in the mouse embryo heartAnatomy and Embryology 211:95–100.https://doi.org/10.1007/s00429-005-0065-x
CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivoJournal of Clinical Investigation 105:1395–1406.https://doi.org/10.1172/JCI8551
Ontogeny of humoral heart rate regulation in the embryonic mouseAmerican Journal of Physiology. Regulatory, Integrative and Comparative Physiology 281:R401–R407.
Tissue specificity and alternative splicing of the Na+/Ca2+ exchanger isoforms NCX1, NCX2, and NCX3 in ratThe American Journal of Physiology 272:C1250–C1261.
Excitation-contraction coupling of the mouse embryonic cardiomyocyteJournal of General Physiology 132:397–405.https://doi.org/10.1085/jgp.200809960
Functional expression of the Na+/Ca2+ exchanger in the embryonic mouse heartJournal of Molecular and Cellular Cardiology 42:121–132.https://doi.org/10.1016/j.yjmcc.2006.10.008
The Na+-Ca2+ exchanger is essential for the action of cardiac glycosidesCirculation Research 90:305–308.https://doi.org/10.1161/hh0302.104562
Hypertrophy and heart failure in mice overexpressing the cardiac sodium-calcium exchangerJournal of Cardiac Failure 13:318–329.https://doi.org/10.1016/j.cardfail.2007.01.004
MesP1: a novel basic helix-loop-helix protein expressed in the nascent mesodermal cells during mouse gastrulationDevelopment 122:2769–2778.
Intracellular Ca2+ oscillations, a potential pacemaking mechanism in early embryonic heart cellsJournal of General Physiology 130:133–144.https://doi.org/10.1085/jgp.200609575
Analyzing real-time PCR data by the comparative C(T) methodNature Protocols 3:1101–1108.https://doi.org/10.1038/nprot.2008.73
Accelerated onset of heart failure in mice during pressure overload with chronically decreased SERCA2 calcium pump activityAJP: Heart and Circulatory Physiology 286:H1146–H1153.https://doi.org/10.1152/ajpheart.00720.2003
Molecular pharmacology of the amiloride analog 3-amino-6-chloro-5-[(4-chloro-benzyl)amino]-n-[[(2,4-dimethylbenzyl)-amino]iminomethyl]-pyrazinecarboxamide (CB-DMB) as a pan inhibitor of the Na+-Ca2+ exchanger isoforms NCX1, NCX2, and NCX3 in stably transfected cellsJournal of Pharmacology and Experimental Therapeutics 331:212–221.https://doi.org/10.1124/jpet.109.152132
Functional embryonic cardiomyocytes after disruption of the L-type alpha1C (Cav1.2) calcium channel gene in the mouseJournal of Biological Chemistry 275:39193–39199.https://doi.org/10.1074/jbc.M006467200
Fetal and postnatal development of Ca2+ transients and Ca2+ sparks in rat cardiomyocytesCardiovascular Research 58:535–548.https://doi.org/10.1016/S0008-6363(03)00255-4
Early cardiac development: a view from stem cells to embryosCardiovascular Research 96:352–362.https://doi.org/10.1093/cvr/cvs270
Na/Ca exchange: regulator of intracellular calcium and source of arrhythmias in the heartAnnals of the New York Academy of Sciences 1099:315–325.https://doi.org/10.1196/annals.1387.033
Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channelsJournal of Clinical Investigation 116:3127–3138.https://doi.org/10.1172/JCI26620
Targeted disruption of Na+/Ca2+ exchanger gene leads to cardiomyocyte apoptosis and defects in heartbeatJournal of Biological Chemistry 275:36991–36998.https://doi.org/10.1074/jbc.M004035200
Hierarchical grouping to optimize an objective functionJournal of the American Statistical Association 58:236–244.https://doi.org/10.1080/01621459.1963.10500845
Natural and synthetic regulators of embryonic stem cell cardiogenesisPediatric Cardiology 30:635–642.https://doi.org/10.1007/s00246-009-9409-2
CaMKIIdelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responsesJournal of Biological Chemistry 282:35078–35087.https://doi.org/10.1074/jbc.M707083200
Margaret BuckinghamReviewing Editor; Institut Pasteur, France
In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.
[Editors’ note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The previous decision letter after peer review is shown below.]
Thank you for choosing to send your work entitled "Calcium handling precedes cardiac differentiation to initiate the first heart beat" for consideration at eLife. Your full submission has been evaluated by Janet Rossant (Senior editor) and three peer reviewers, as well as a member of our Board of Reviewing Editors, and the decision was reached after discussions between the reviewers. Based on our discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in eLife.
We appreciate the importance of this study on the establishment of calcium gradients and its implications for cardiogenesis. We also appreciate the technical advances in this paper which presents a multidisciplinary approach and includes functional studies. However, a number of points raised by the reviewers indicate problems with the paper as it stands. Notably new mechanistic insights are weak. There is a lack of data on LTCC Cav1.3. The mechanistic link between early NCX-1 dependent asyncronous activity and maturation of electrical activity and excitation contraction coupling is lacking – blocking experiments in embryo culture are inadequate. There is also a question about novelty. The Introduction is weak and does not adequately cover current available papers on the subject. Reconsideration of experimental approaches in the context of earlier studies should lead to the design of further experiments such as genetic ablation of key components or electrical measurements in embryo culture.
We consider that the issues raised by the reviewers cannot be addressed in the short time frame required by eLife for return of a revised manuscript. However, we would encourage you carry out further experiments and if you then feel that you have addressed all the issues, eLife remains open to receiving a revised manuscript in the future for consideration as a new submission.
The authors present an interesting study demonstrating calcium-mediated contractile activity in the mouse cardiac crescent earlier than previously thought. The study is strengthened by the use of both embryonic data and ESC-derived cardiomyocyte data. The experiments follow a logical progression with the data and figures presented clearly. I recommend accepting the manuscript with revision and additional experiments.
While concise scientific communication is appreciated, the Introduction is a bit too concise (one paragraph composed of three sentences). The manuscript would benefit from additional background and justification for the current study.
Given the strength of the assertion that this study is a definitive analysis of early crescent contractility, the sarcomere immunostaining should be more thorough and expanded to include other sarcomeric proteins that spatiotemporally indicate sarcomere formation. Although the current data is supportive of the conclusions presented, cTnT alone is not sufficient in this regard. At minimum, immunostaining for α-actinin, a Z-disc protein would much improve and strengthen this data. Further, inclusion of staining for myomesin, an M-band protein would be much more definitive especially if double stained showing alternating actinin/myomesin.
The gene expression studies should be complemented by whole mount in situ hybridization. This is especially important for Figure 4 as neither Slc8a1 or Cacna1c are solely restricted to the heart and the gene expression was performed on whole embryos.
More information is needed to evaluate the gene expression studies. At minimum, primer details, amplicon details, replicates (both biological and technical) and PCR parameters should be reported. In the absence of validating the reference genes for qPCR, what is the rationale for choosing HPRT for in vivo samples and GAPDH for ESCs? How is fold change calculated? Is it in relation to E7.5 for embryos and D0 for ESCs? The following references should be helpful in this regard.
Johnson G, et al. Methods Mol Biol. 2014;1160:5-17.
Bustin SA, et al.. Nat Methods. 2013 Nov;10(11):1063-7.
Bustin SA, et al. BMC Mol Biol. 2010 Sep 21;11:74.
The manuscript addresses the earliest stages of electrical activity in the mammalian heart and ES cell-derived EBs and in particular the relative requirements of the Na/Ca exchanger NCX1 and L-type Ca channel (LTCC). The main implications of the work are when Ca transients are established and how this relates to cardiogenesis. In general, the work is well written and the data interesting and relevant to the above issues. The functional and multidisciplinary approach to cardiac development is a strength. For the most part the experiments are carefully performed and results make a strong contribution.
1) The novelty of the findings are diminished somewhat by prior publications on genetic deletion of NCX and LTCC genes in mice and fish. The novelty of this study lies in the detailed assessment of beating, Ca transients, and relative requirements for NCX1 and LTCCs. I recommend that some of the material relegated to the Discussion come forward to the Introduction to make clear the state of the field including the broad findings relating to NCX1 and LTCC pharmacological and genetic inhibition in the context of embryogenesis, and the novelty of the present findings in a summary paragraph. Background studies should cover what has been observed in the chick embryo wrt beating and pacemaker function, and electrophysiology.
2) The text is not rigorous in defining the dose of drugs used and the duration of use in each experiment. Different doses and treatments are mentioned. In addressing the relative requirements for NCX1 and LTCCs, dose response data would seem important as different drugs may have different Ki etc. It seems important to address this formally throughout or to do specific experiments that incorporate dose responses.
3) Furthermore, rationale is not given for differing doses between experiments e.g. for CB-DMB is used at 20 μm in experiments shown in Figure 5A-F but at 1mM in those in Figure 6A-D. This is a massive difference. The authors must provide full rationale for these choices in light of the issue raised under point 2.
4) The experimental design in the experiment described at the end of page 8 onwards does not allow the stated conclusions to be drawn. First, duration of drug treatment is unknown. Second, the design of the sequential experiment is informative but does not allow the authors to conclude that the earlier NCX-1-dependent waves are essential for subsequent differentiation and beating.
5) In the last paragraph of the subsection “NCX1 is essential for the initiation of Ca2 transients in the developing cardiac crescent”. the effects on GFP from Nkx2-5GFP should be quantified, preferably by FACS.
6. In the last paragraph of the subsection “NCX1 is essential for the initiation of Ca2 transients in the developing cardiac crescent”. This is a key experiment that addressed an important theme for the paper; the response of the cardiac network to inhibition of NCX1 and LTCC was poorly analysed (only 4 genes analysed, two of these encoding the channels, and only at one time point). Effects could be secondary.
7) In the subsection “Inward Ca2 via NCX1 and downstream CAMKII signalling promotes cardiomyocyte differentiation”; inhibition of beating in low Ca is not surprising. How do the results show that Ca is required for maturation and differentiation?
8) In the subsection “NCX1 is essential for cardiac crescent formation during development”. For such an important point, actin staining of embryos treated with inhibitors and PCR are insufficient to draw the broad conclusion that there is a lack of crescent cells. This experiment needs far more development. What happens to the pre-cardiac cells and cardiac progenitors over time needs to be analysed with appropriate markers?
The manuscript "Calcium handling precedes cardiac differentiation to initiate the first heart beat" by Tyser et al. tries to address the importance of calcium cycling for cardiac crescent formation in the embryonic heart by Ca2 imaging, gene expression analysis and pharmacological blocking during culture of mouse embryos and embryonic stem cells. The main result is that the sodium-calcium-exchanger (NCX) is important for cardiomyocyte development and function because pharmacological block of NCX reduces Ca2 transients and beating as well as lowers expression of cardiac genes and delays cardiac crescent formation.
Although the manuscript presents major technical advancements in this field including mouse embryo culture and recording of Ca2 transients from the cardiac crescent prior to beating, the study remains descriptional and the proposed mechanism is based on over interpretation of results and assumptions including drug specificity of long term drug application.
Most importantly the authors have not measured or discussed the involvement of voltage signals in cardiomyocytes and several other known facts on the physiology of embryonic heart cells or on the pacemaking mechanism in the embryonic heart.
The authors write "NCX1, have not previously been implicated in the initiation event of cardiac contraction, nor investigated at the earliest stages of heart development coincident with the onset of beating" and in the Abstract "how the initial contractions are established have not been described". This is incorrect. It is well known that in the embryonic heart cell, a periodic intracellular calcium oscillation (IP3-dependent) is driving pacemaking and translated into voltage fluctuations specifically by the NCX (forward mode of the electrogenic pump). These fluctuations can induce action potentials that synchronize the cardiac tissue and therefore NCX is essential for cardiac development (please see for instance: Excitation-Contraction Coupling of the Mouse Embryonic Cardiomyocyte" Rapila R et al. 2008 and the other papers by the Tavi group or "Intracellular Ca2 Oscillations, a Potential Pacemaking Mechanism in Early Embryonic Heart Cells" Sasse P et al. 2007).
Furthermore, it is well known that intact Ca2 cycling is important for cardiac gene expression and heart development. The authors should clearly cite the previous work and specifically describe the novelty and mechanism of their study.
The main conclusion of the blocker experiments is that NCX reverse mode is important for Ca2 entry and gene regulation but how this should induce periodic beating or pacemaking has not been addressed or discussed. NCX and can only work in reverse mode when intracellular Na concentration is excessively high during an action potential (although controversial if this really happens, or if the effect is only a less effective forward mode). This has not been shown for embryonic cardiomyocytes and is highly unlikely because of the lack of Na channels or Na driven action potentials at this stage.
The (confusing) idea of a reverse mode NCX comes from the literature that state that at low dosages (EC50 in the low µM range) KB-R is preferential blocking a reverse mode. Although oocyte experiments with non-physiological intracellular Na concentrations suggest this, other experiments on cardiomyocytes (e.g. "Direction-independent block of bi-directional Na /Ca2 exchange current by KB-R7943 in guinea-pig cardiac myocytes" by Kimura, J et al. 1999) show that this specificity is not existent and other papers show that this is highly depending on intracellular Na concentrations and drug dosage used. Thus without electrophysiological analysis, it remains unclear, if the inhibitory effect on beating and cardiac crescent formation after block of NCX by KB-R or CB-DMB is due to effects on of Ca2 oscillations, pacemaking, translemmal Ca2 entry or exit, membrane potential fluctuation, synchronization by action potentials, imbalance of Ca2 homeostasis or off-target effects that occur especially when applied long term.
In summary, the presented data, although in part novel and interesting, together with the known literature on embryonic cardiomyocytes and on the physiology of ECC, LTCC and NCX function does not allow to conclude a mechanism.
Specific major points:
The Introduction is too short and only very general. Specifically, several known facts on initiation of the first heart beat and the role of calcium gene regulation during embryonic heart development should be cited. For instance, several earlier publications have tried to address "the important question of when and how contractile activity of cardiomyocytes is first initiated during development" (see above). In addition to cite these earlier work in introduction it should be better pointed out, why these earlier studies are not sufficient and the current study is required (which is easy, because of the nice in vivo data).
Also the first paragraph of the section "A role for the Sodium-Calcium exchanger…" belongs to the Introduction. Please describe the well-known ECC in the adult heart a bit less but introduce more the known facts on ECC and the importance of NCX for pacemaking in the embryonic heart (see above).
Because of the low resolution of the supplied PDF file, the cardiac maturation and cross striation at the different crescent sages is difficult to review. Maybe providing inserts to highlight the specific patterns (especially stage 1 2) would help. Is cross striation completely absent in stage 0?
The finding of Ca2 transients at stage 0 is fascinating. Maybe better call them "spontaneous asynchronous Ca2 oscillations" also to highlight the difference semantically to the (action potential-based?) coupled transients at stage 1 . What is the average frequency and is there a correlation between frequency and TTP (maybe more interesting to show than TTP vs TT1/2M which lacks a conclusion)? Is there evidence that transients are coupled between individual cells (from the video this seems to be sometimes the case). Although not in the scope of the authors´ manuscript, recording of membrane potential is essential to understand the nature of cell-cell coupling of these fascinating data.
Figure 3: Normalizing gene expression data to D0 or E7.5 (where most genes are not expressed) make less sense, adds noise and masks information. Please consider normalization to the time point of the highest value.
Unfortunately, Cacna1d (Cav1.3), which is the dominant isoform of LTCC in the early embryo (see "Subtype switching of L-Type Ca 2 channel from Cav1.3 to Cav1.2 in embryonic murine ventricle". Takemura H et al. 2005) was not analyzed and therefore the expression data of Cacna1c does not suggest a minor role of LTCC, but just highlights the well-known isoform switch (see also "Functional Embryonic Cardiomyocytes after Disruption of the L-type α1C (Cav1.2) Calcium Channel Gene in the Mouse"). The analysis of other LTCC genes or western blot at different stages from heart tissue might help in this regard.
The establishment of an embryo culture for investigation of cardiac crescent or heart tube formation as well as for gene expression analysis is a definite plus and a main methodological advancement of this paper. Very nice! However, the fact that "Embryos cultured in CB-DMB were delayed in terms of cardiac crescent formation" is not supported by the one actin image shown (Figure 6O) although it is one of the main messages of the paper. Repeating of experiments, extensive histological analysis by specific crescent staining, and quantitation is suggested. Also a time course analysis of crescent formation with and without CB-DMB and KBR would enhance the paper. How many hours are the cardiac crescent forming delayed under NCX blockage?
Was the data in Figure 5A, B, E, F obtained from Ca imaging or from video microscopy? If here video microscopy was used, also data from Ca imaging should be added to see the acute (>1-2 minutes) effects of the three blockers on Ca2 transients and remaining Ca2 oscillations (before all Ca2 has left the cell and the impaired Ca2 homeostasis is blocking pacemaking).
In the Discussion the authors have claimed to use "two independent pharmacological channel blockers CB-DMB and KB-R7943, in embryo cultures", but only show CB-DMB data in Figure 6. Please also show the KB-R data on embryonic cultures.
The authors describe “sequential addition of CB-DMB to nifedipine-treated embryos after 15 mins, subsequently blocked the transients that were refractory to LTCC inhibition (not shown)." Please provide the data and statistics and explain the mechanism. What is the percentage of transients that were not blocked by LTCC inhibition? Was this observed at all stages or is this stage specific?
[Editors’ note: what now follows is the decision letter after the authors submitted for further consideration.]
Thank you for submitting your article "Calcium handling precedes cardiac differentiation to initiate the first heartbeat" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Janet Rossant as the Senior Editor. The reviewers have opted to remain anonymous.
The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.
The manuscript resubmitted after revision is much improved and is now under review with a view to publication of these interesting findings. The authors show that the sodium calcium exchanger (NCX) early, at what they define as stage 0, is essential for generating spontaneous asynchronous Ca2 oscillations (SACO) in the cardiac crescent and that these are essential for cardiac gene expression and subsequent development. However, interpretation of the results and the proposal that reverse mode NCX, allowing Ca2 to enter the cell, is involved in the mechanism are still problematic.
Firstly, in the experiments with inhibitors, the stage 0 experiments are critical. The authors use nifedipine to block voltage dependent Ca2 channels (VDCC), which interestingly at stage 0 has less effect on SACO, in contrast to later stages when it blocks activity. CB-DMB, which blocks NCX, affects SACO at stage 0, but it also blocks Ca2 exit mode. In the manuscript KB-R7943 is claimed to specifically block reverse mode NCX but it was not used at stage 0. This result should be shown. The finding that this inhibitor blocks activity at stages 1 and 2 is not so important because nifedipine does this too. In their interpretation the authors should be aware of controversy about the action of KB-R7943.
The SACO shown in Figure 2D and Video 3 is one of the most important pieces of data and in fact is the major novelty. Please provide more data here including n-numbers, statistics and report reproducibility of these findings. Are SACO observed in every stage 0 embryo? What is the Ca2 cycling frequency and amplitude and how often are single uncoupled (Figure 2D´) and multiple coupled cells (Figure 2D´´) observed?
The experiments on blocking SACO with CB-DMB in contrast to nifedipine lead to one of the most important findings, however the analysis and statistics are very limited. Please provide absolute numbers of cells with SACO and original data (example traces, videos) to enable the reader to follow the analysis and statistics. Line 310: What does "0.87 0.083, mean SEM" refer to? How are cells without SACO identified if they do not show Ca2 signals? How is the variance of cells with SACO per embryo? ANOVA comparisons are required to take these variations in control embryos into account.
The novel Figure 3—figure supplement 1E on RyR/APD treatment is confusing as it does not follow the authors (very good) stage classification (stage 0, 1, 2, 3, LHT) but has a novel classification (turned/pre-turned embryo). Please label data as stage 0, stage 1 and LHT, at least. Please add statistics, error bars and original Ca2 imaging traces. A DMSO control for stage 3 is missing.
Figure 4 A, B, E, F: the error bars are missing. In fact, it is not even fully clear from the methods what% inhibition means. Please discriminate between complete block of beating (movement in DIC images), reduction of frequency, complete block of Ca2 transients and reduction of Ca2 transient amplitude. Also please provide time courses and report the delay of drug action (should be easy as Ca2 imaging was performed at baseline and at 5, 15 and 30 minutes post drug treatment).
In general, in the text it is important to clarify what is meant by inhibition and partial inhibition.
Although the pharmacological block using CB-DMB shown in Figure 4I-L lets the authors conclude that Ca2 entry though NCX is the basis for the SACO, the mechanism of how this could be periodic and lead to oscillations in Ca2 is unclear. The authors are correct that NCX can (under special circumstances such as elevated intracellular Na or depolarized membrane potential) lead to Ca2 entry, but once this occurs, the electrogenic nature of NCX (~3 Na for 1 Ca2 ) will again hyperpolarize the cell and export Na until the equilibrium potential is reached and Ca2 flux ceases. Thus it is not possible that the NCX can generate periodic Ca2 oscillations alone. Reverse mode only occurs if periodic action potentials are depolarizing the cell but then cells should be synchronized (no SACO). Maybe Na levels are cycling or the Na/K-ATPase is involved? This could be clarified by testing whether SACO at stage 0 are blocked by RyR/2-APB or by SERCA blockers (Thapsigargin/CPA). These mechanistic considerations should be taken into account in the authors' Discussion.
On the mechanistic front, as it stands the paper does not permit definitive conclusions; the authors must be less dogmatic about the SACO/Ca2 cycling mechanism and introduce notes of caution in their Discussion. The authors are encouraged to attempt electrophysiological analysis since without this it remains unclear if the inhibitory effect on beating and cardiac crescent formation of NCX by KB-R7945 or CB-DMB is due to effects on SACO, translemmal NCX reverse mode Ca2 entry (mechanism unclear) or NCX forward mode Ca2 exit (NCX block-based Ca2 overload can also inhibit gene expression), imbalance of Ca2 homeostasis or off-target effects. These analyses as well as straight forward siRNA experiments, proposed in the first reviews prior to resubmission, should be feasible with the elegant embryo culture technology set up by the authors.
A second aspect which requires further revision is the gene expression data. This should be normalised relative to housekeeping control genes. Normalising to E7.75 when most genes are not expressed and there is mainly noise is not informative, preventing meaningful comparison between genes. For instance, in the current presentation the time course of NCX and Cav1.3 seems to be superimposable. The data should be represented as dCT (normalised only to housekeeping genes) and then the meaningful differences in time course/relative levels discussed.
[Editors' note: further revisions were requested prior to acceptance, as described below.]
Thank you for resubmitting your work entitled "Calcium handling precedes cardiac differentiation to initiate the first heartbeat" for further consideration at eLife.
Before publication, the following remaining concerns of one reviewer will need to be addressed:
1) Please provide information on the frequency, duration and regularity of SACO at stage 0 as requested and as stated in the subsection “The onset of Ca2 -handling in the cardiac crescent” ("variable frequencies and durations"). From the authors comment in the rebuttal and from Video 4 (very nice) it is well understandable that precise numbers are difficult to give but at lease state something like "Compared to Ca2 transients at later stages (Figure 2A) the SACO were rare. During a ~20 s recording period we observed only 10.3 -x individual SACO per embryo (n=24) occurring in different sites. Consecutive SACO in a same site were rarely observed within the 20 s imaging windows and therefore we conclude that SACO in individual cells occur at a frequency < 3 bpm."
2) Please describe the meaning of Figure 2—figure supplement 1C with something like "During a SACO, Ca2 rises slowly and reaches the peak between 0.5 and 10 s. Cells with slow Ca2 influx also showed similar slow Ca2 efflux (Figure 2—figure supplement 1C)."
3) Because of the very slow nature of SACO, also oscillations in energy production and ATP levels can be involved (in fact the most likely explanation of SR is not involved). Please add this to the Discussion (fourth paragraph).
4) The authors state that Ryanodine 2-APB only affected embryos that had already undergone cardiac looping but the earliest stage tested was stage 3. Although requested, the effect of Ryanodine 2-APB on SACO was not analyzed. Thus it seems to be fair to include in the revised Discussion on the SACO mechanism (fourth paragraph) something like: "Because we have not tested the involvement of SR function at stage 0, we cannot fully exclude that periodic Ca2 releases from the SR are involved in the generation of SACO as reported before as a pacemaking mechanism in early embryonic cardiomyocytes (cite adequate references).https://doi.org/10.7554/eLife.17113.025
- Richard CV Tyser
- Antonio MA Miranda
- Shankar Srinivas
- Paul R Riley
- Shankar Srinivas
- Shankar Srinivas
- Shankar Srinivas
- Paul R Riley
- Paul R Riley
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
This work was generously supported by the British Heart Foundation (RCVT, AMAM, SMD; CH/11/1/28798 and RG/13/9/303269 to PRR) including core support from the BHF Oxbridge Regenerative Medicine Centre (RM/13/3/30159), the BBSRC (REI BB/F011512/1 to SS) and The Wellcome Trust (C-mC; WTSIA 103788/Z/14/Z and 105031/C/14/Z to SS). We thank Liz Robertson for provision of the Eomes-GFP ESC line and Sean Wu for the Nkx2.5-eGFP ESC line.
Animal experimentation: All animal experiments were carried out according to UK Home Office project license PPL 30/3155 Compliant with the UK Animals (Scientific Procedures) Act 1986.
- Margaret Buckingham, Reviewing Editor, Institut Pasteur, France
- Received: April 20, 2016
- Accepted: September 13, 2016
- Version of Record published: October 11, 2016 (version 1)
© 2016, Tyser et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.